Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.
Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.
Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.
Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.
For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Horizon Therapeutics has shared promising data from the PROTECT trial, supporting KRYSTEXXA (pegloticase injection) for treating uncontrolled gout in kidney transplant patients. Presented at the ASN Kidney Week 2020, the trial indicates that patients receiving KRYSTEXXA showed significant reductions in serum uric acid levels. Among 15 enrolled patients, 5 completed treatment with sustained improvements, while 8 continued. The research highlights the drug's potential effectiveness without compromising kidney function, addressing a critical need among this vulnerable population.
Horizon Therapeutics plc (Nasdaq: HZNP) has announced new long-term data from its Phase 2 clinical trial of TEPEZZA (teprotumumab-trbw), showing sustained benefits in patients with Thyroid Eye Disease (TED) up to one year post-treatment. Key findings include that 97% of participants improved their clinical activity score and 70% achieved disease inactivation. TEPEZZA is the only FDA-approved treatment for TED, addressing a critical need for patients facing severe symptoms. These promising results support ongoing clinical evaluation and indicate the potential of TEPEZZA for long-term symptom relief.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that new data on KRYSTEXXA (pegloticase injection) will be presented at the upcoming ACR Convergence conference from Nov. 5-9, 2020. This includes results from the RECIPE trial aimed at reducing immunogenicity of pegloticase in patients with uncontrolled gout. Presentations will focus on the impact of co-prescribing KRYSTEXXA with immunomodulators. Additionally, the company will host a discussion on Nov. 10 about these findings and their implications for treatment. Safety data indicate that the combination therapy's effectiveness remains unverified by health authorities.
Horizon Therapeutics plc (Nasdaq: HZNP) will announce its third-quarter 2020 financial results on November 2, 2020. A live webcast is scheduled for 8 a.m. Eastern Time to discuss the financial and operational performance. Interested parties can access the live stream and replay via the company's investor relations website.
Horizon focuses on developing medicines for rare and rheumatic diseases, aiming to provide clinically meaningful therapies through scientific expertise and compassion.
HemoShear Therapeutics has achieved a significant milestone in its collaboration with Horizon Therapeutics (NASDAQ: HZNP) for developing new gout therapies. The partnership, initiated in January 2019, has led to valuable insights and the receipt of an undisclosed milestone payment. The collaboration could yield over $500 million in potential milestone payments and royalties for HemoShear. Additionally, HemoShear has received FDA approval to start a Phase 2 study for its oral drug targeting methylmalonic acidemia and propionic acidemia.
FAQ
What is Horizon Therapeutics?
What products does Horizon Therapeutics offer?
What recent achievements has Horizon Therapeutics made?
Who is acquiring Horizon Therapeutics?
How is Horizon Therapeutics contributing to medical science?
What is the mission of Horizon Therapeutics?
How can I learn more about Horizon Therapeutics?
What is the significance of Horizon’s recent agreement with the FTC?
Where is Horizon Therapeutics headquartered?
What is the focus of Horizon's research and development efforts?
